Series B Round of $130M Fuels NewLimit Mission to Advance AI Cellular Rejuvenation Science

NewLimit, a biotechnology company developing epigenetic reprogramming therapies to extend healthy human lifespan, has raised $130 million in Series B funding. The round was led by Kleiner Perkins, with participation from new investors Nat Friedman, Daniel Gross, and Khosla Ventures, alongside returning backers including Founders Fund, Dimension Capital, Elad Gil, Garry Tan, and Patrick Collison.

Co-founded by Coinbase CEO Brian Armstrong, biotech investor Blake Byers, and stem cell scientist Jacob Kimmel, NewLimit has developed three prototype medicines that restore youthful function to aged liver cells. Using a closed-loop AI platform to simulate and test drug candidates, the company plans to accelerate preclinical development as it prepares for eventual human trials.